Piper Jaffray Downgrades Impax Laboratories (IPXL) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Impax Reports Fourth Quarter and Full Year 2016 Financial Results
March 1, 2017 6:35 AM ESTFORT WASHINGTON, Pa., March 1, 2017 /PRNewswire/ --Â Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced financial results for the fourth quarter and full year 2016.
Fourth Quarter 2016
Total revenues in the fourth quarter of 2016 decreased 29.7% to $198.4 million, compared to $282.1 million in the fourth quarter of 2015, due primarily to increased competition and/or lower pricing on generic diclofenac sodium gel 3%, metaxalone, fenofibrate and mixed amphetamine salts ER. The decline was partially offset by the addition of products acquired from Teva Pharmaceuticals Industries Ltd. and affiliates... More